Latest News

Legend Biotech recently reported that more than 10,000 patients have now been treated with its CARVYKTI therapy and that it has expanded production with what it describes as the largest cell therapy manufacturing facility in the U.S., while guiding that it aims to reach profitability in 2026. Beyond the headline numbers, the combination of scaled CARVYKTI manufacturing and progress on its in vivo cell therapy pipeline suggests a company increasingly geared toward broader clinical use and...

Wayfair (W) is back in focus after helping Google create the Universal Commerce Protocol, an open standard that connects AI agents with retailers and supports direct checkout from Google product listings. See our latest analysis for Wayfair. The Google partnership lands at a time when momentum in Wayfair’s shares has been strong, with a 1 month share price return of 22.34% and a 90 day share price return of 46.41%, while the 1 year total shareholder return of 178.74% contrasts with a 5 year...

Recent commentary on LKQ Corporation highlights that over the past two years the global auto parts distributor has seen no organic revenue growth, raising concerns that it may increasingly depend on acquisitions to expand its business. At the same time, stagnant free cash flow margins and weakening returns on capital are prompting fresh questions about how effectively management is allocating resources across the portfolio. Next, we’ll examine how concerns about stalled organic growth and...

If you are wondering whether Daiichi Sankyo Company’s current share price reflects its true worth, you are not alone. This article is designed to help you make sense of that question. The stock last closed at ¥3,540, with returns of 2.6% over 7 days, 5.3% over 30 days, a modest 0.3% year to date, and a 13.1% decline over 1 year. The 3 year and 5 year returns sit at 9.7% and roughly 0% respectively. Recent coverage of Daiichi Sankyo has focused on its position in the pharmaceuticals and...

Why New Murchison Gold is on investors’ radar today New Murchison Gold (ASX:NMG) has drawn fresh attention after reporting high grade drilling results from the Lydia Project, extending the Lydia shear zone and supporting plans to progress the prospect toward production. See our latest analysis for New Murchison Gold. That Lydia update comes on the back of strong recent momentum, with a 90 day share price return of 106.67% and a very large 1 year total shareholder return, suggesting sector...

Fair Isaac (FICO) is back on investors’ radar after recent share price swings, with the stock showing a negative return over the past month and the past year, alongside a strong 3 year total return. See our latest analysis for Fair Isaac. At a share price of US$1,623.18, Fair Isaac’s recent 12% 1 month share price decline and 1 year total shareholder return of 17% loss contrast with its large 3 year total shareholder return. This suggests that momentum has cooled after a multi year period in...

Bechtle (XTRA:BC8) is back in focus after a reported slide in return on capital employed from 15% to 12% over five years, raising fresh questions about how efficiently its reinvested cash is working. See our latest analysis for Bechtle. At a share price of €44.36, Bechtle has a 90 day share price return of 25.52%, while the 1 year total shareholder return of 52.57% contrasts with a 5 year total shareholder return decline of 17.95%, suggesting momentum has picked up recently even as longer...

Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-year 2025 results indicating approximately 12% quarterly and 9% annual revenue growth. Management also highlighted a record level of incremental contract value from new and expanded hospital agreements, underscoring the importance of long-term customer relationships to the business. We’ll now examine how the record incremental...

In early January 2026, Takeda and Protagonist Therapeutics announced that they had submitted a New Drug Application to the U.S. FDA for rusfertide, a first-in-class subcutaneous hepcidin mimetic for adults with polycythemia vera, supported by positive Phase 3 VERIFY and Phase 2 REVIVE trial results and multiple expedited regulatory designations. This filing is important because rusfertide targets the underlying iron dysregulation mechanism in polycythemia vera and, if approved, could offer a...

Leerink Partners recently initiated coverage on Inventiva with an Outperform rating and a US$12.00 price target, following earlier positive views from UBS and Wolfe Research on the company’s lead NASH/MASH candidate lanifibranor. At the same time, Inventiva secured about US$172.5 million in planned equity financing alongside a US$150 million ADS offering, reinforcing funding for the fully enrolled Phase 3 NATiV3 trial in a disease area that still has no approved therapies. We’ll now examine...

Champion Iron (ASX:CIA) reported that rail services on the Quebec North Shore and Labrador Railway are gradually back online after a third party derailment disrupted shipments from its Bloom Lake iron ore operations. See our latest analysis for Champion Iron. The latest rail update comes after a strong run in the shares, with a 31.08% 90 day share price return, while the 1 year total shareholder return of 15.30% points to momentum that has been building rather than fading. If this kind of...

In recent days, National Australia Bank has advanced its digital transformation with the Harness platform and launched its enterprise-wide ‘Your Partner for Every Stage’ brand campaign, while investors watch upcoming Reserve Bank of Australia decisions and the bank’s February trading update. Together, these technology and brand initiatives highlight NAB’s push to streamline operations and strengthen customer relationships in a tightly regulated banking landscape. We’ll now examine how NAB’s...

In early January 2026, BrightInsight reported improved adherence and persistence from its Patient App for a key Sanofi–Regeneron biologic, while Sanofi also expanded its immunology footprint through a potential US$2.56 billion-plus autoimmune collaboration with Earendil Labs and advanced Tzield via US priority review in young children and European approval to delay type 1 diabetes progression. These developments highlight how Sanofi is pairing digital tools with regulatory progress in...

Gen Digital (GEN) is in focus after renewed attention on its shift from traditional antivirus products to a unified AI-driven cyber safety platform that bundles security, identity and privacy tools into subscription offerings. See our latest analysis for Gen Digital. At a share price of US$26.28, Gen Digital’s recent 1 month share price return of 5.02% and 1 year total shareholder return of 1.46% contrast with its 3 year total shareholder return of 23.96% and 5 year total shareholder return...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Mennica Skarbowa S.A. ( WSE:MNS ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Key Insights The projected fair value for Inspiration Healthcare Group is UK£0.099 based on 2 Stage Free Cash Flow to...

Alvopetro Energy (TSXV:ALV) just reported its December 2025 and fourth quarter sales volumes, with the quarter at 2,867 boepd versus 2,343 boepd a year ago, drawing fresh attention to the stock. See our latest analysis for Alvopetro Energy. These volume figures arrive as Alvopetro Energy’s share price sits at CA$6.88, with recent momentum reflected in a 12.23% 1 month share price return and a 46.73% 1 year total shareholder return, suggesting interest has been building over time. If this...

Moody’s Corporation recently elected Lisa P. Sawicki, a former Global Board Chair at PricewaterhouseCoopers with over 35 years’ audit and financial services experience, to its Board of Directors, with her appointment becoming effective on March 16, 2026. Sawicki’s addition to the Audit and Governance & Nominating committees reinforces Moody’s focus on governance quality and risk oversight at a time when regulatory expectations on financial institutions are evolving. We’ll now examine how...

Why Cummins Stock Is Back in Focus After Its Latest Earnings Cummins (CMI) is back on investors’ radar after a quarterly report that surpassed EBITDA and revenue estimates, supported by stronger profitability in Power Systems and Distribution and demand for backup power for data centers. See our latest analysis for Cummins. The earnings beat has arrived alongside strong share price momentum, with a 34.02% 90 day share price return and a 58.90% 1 year total shareholder return suggesting...

How Doximity’s Recent Performance Sets the Stage for Investors Doximity (DOCS) has been on many investors’ watchlists after a mixed stretch in its share price, with negative returns over the past week, month and past 3 months drawing closer attention. At a recent close of US$41.36, the company shows a value score of 4 and an intrinsic discount of about 20%, while still carrying a positive 3 year total return of roughly 28%. See our latest analysis for Doximity. Recent share price moves have...

Honat Bancorp (HONT) has put another solid quarter on the board, with Q2 2025 revenue of US$11.4 million and basic EPS of US$2.57 feeding into trailing twelve month EPS of US$10.46 on revenue of US$44.6 million and net income of US$15.0 million. Over the past year, the company has seen revenue move from US$38.8 million to US$44.6 million on a trailing basis, while EPS climbed from US$8.33 to US$10.46, and earnings growth of 19% has supported a net profit margin of 33.5% compared with 31.2% a...